KOSPIBiotech & Pharma207940

Samsung Biologics

₩1,376,000▼ 2.69%2026-11-18 close
Market Cap
₩63.7T
Turnover
₩34.6B
Volume
30K
Shares out.
46.3M
PER
36.3×
PBR
7.5×
EPS
₩38,905
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Earnings recovering; new orders are the key test

Revenue and operating profit have risen for three straight quarters, while profit attributable to controlling shareholders has fallen for four, so new orders and the timing of the sixth plant are the next checkpoints.

  1. 1

    The 2025 operating margin rose to 45.4% from 29.0% in 2024, while revenue grew only 0.2% that year.

  2. 2

    Q3 2026 revenue was KRW 1.49 trillion and operating profit KRW 640.1 billion, and the company raised its annual revenue growth guidance to 20%.

  3. 3

    Profit attributable to controlling shareholders fell for four straight quarters, from KRW 574.5 billion in Q3 2025 to KRW 391.1 billion in Q3 2026.

  4. 4

    A contract disclosed on November 3, 2026, worth about KRW 434.3 billion, lifted cumulative orders to USD 22.3 billion, and 2026 year-to-date orders were reported at about KRW 1.5 trillion (USD 1.1 billion).

  5. 5

    Tendered shares of 87.88% in the PolyPeptide Group tender offer position the company to expand into peptide CDMO.

02

Business structure

Samsung Biologics is a contract development and manufacturing organization (CDMO) that provides contract manufacturing (CMO) for biopharmaceuticals and contract development (CDO) services covering process development.

Its production base runs from Plant 1 to Plant 5 in Songdo, Incheon, and in its Q3 2026 disclosure the company said Plants 1 to 4 remain fully utilized.

Plant 5 is in ramp-up, the stage in which capacity is raised step by step after equipment is installed, and the company expects qualification-batch revenue to be recognized in the second half of 2026.

The Rockville facility in the United States, acquired in March 2026, began contributing revenue in Q3 2026, giving the company a local production base in the US.

Cumulative orders as of the Q3 2026 disclosure stood at 117 CMO projects and 184 CDO projects, worth USD 22 billion in total, and rose to USD 22.3 billion after the contract disclosed on November 3, 2026.

The customer base is centered on global pharmaceutical companies, and counterparties are not disclosed until December 31, 2031 for confidentiality reasons. The business is also expanding into peptide CDMO, and the company recorded tendered shares of 87.88% in the tender offer for PolyPeptide Group.

In competition, the company sponsored DCAT Week 2026 alongside global CDMO players such as Lonza and Thermo Fisher Scientific.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.7T₩728.8B43.9%
2025Q4₩308.6B₩378.1B122.5%
2026Q1₩1.3T₩580.8B46.2%
2026Q2₩1.3T₩586.4B44.4%
2026Q3₩1.5T₩640.1B42.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩3T₩983.6B₩798.1B32.8%8.9%84.6%
2023₩3.7T₩1.1T₩857.7B30.1%8.7%63.2%
2024₩4.5T₩1.3T₩1.1T29.0%9.9%59.0%
2025₩4.6T₩2.1T₩1.8T45.4%23.9%48.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

In the annual figures from DART filings, revenue rose from KRW 3 trillion in 2022 to KRW 3.69 trillion in 2023, KRW 4.55 trillion in 2024 and KRW 4.56 trillion in 2025, increasing for three consecutive years from 2023 to 2025. Revenue growth slowed to 0.2% in 2025, so the bulk of top-line expansion came in 2024.

Operating profit grew from KRW 983.6 billion in 2022 to KRW 2.07 trillion in 2025, up 56.8% in 2025 alone. The operating margin fell from 32.8% in 2022 to 30.1% in 2023 and 29.0% in 2024, then jumped to 45.4% in 2025.

Revenue barely grew in 2025 while the operating margin rose 16.4 percentage points, which is the defining feature of that year. Profit attributable to controlling shareholders rose from KRW 798.1 billion in 2022 to KRW 1.78 trillion in 2025, up 64.7% in 2025.

Net profit including non-controlling interests was disclosed at the same amount as controlling-shareholder profit in each year.

By quarter, revenue hit a low of KRW 308.6 billion in Q4 2025, with operating profit of KRW 378.1 billion, and then rose to KRW 1.26 trillion in Q1 2026, KRW 1.32 trillion in Q2 and KRW 1.49 trillion in Q3, increasing for three consecutive quarters.

Operating profit followed the same path, reaching KRW 580.8 billion, KRW 586.4 billion and KRW 640.1 billion.

Profit attributable to controlling shareholders, by contrast, fell from KRW 574.5 billion in Q3 2025 to KRW 510 billion, KRW 469.2 billion, KRW 430.7 billion and KRW 391.1 billion, declining for four consecutive quarters, and was down 31.9% year on year in Q3 2026. The last four quarters total KRW 1.8 trillion.

The company cited full operation at Plants 1 to 4, higher utilization at Plant 5 and Rockville revenue as Q3 growth drivers, and reports said the quarter exceeded market expectations.

The debt ratio fell from 84.6% in 2022 to 48.4% in 2025, with equity of KRW 7.45 trillion and liabilities of KRW 3.61 trillion at year-end 2025. Operating cash flow rose from KRW 953 billion in 2022 to KRW 2.25 trillion in 2025.

05

Industry analysis

A May 2026 Samsung Securities report argued that competition in CDMO is shifting from production cost toward local production capacity.

As US tariff and drug pricing policies changed, biotech companies importing patented drugs produced overseas face choices among accepting price-cut agreements, using US-based CDMOs and bearing tariff costs, the same report noted.

The report judged that Samsung Biologics, with limited US capacity, will find it hard to close the gap quickly with rivals that already have large US infrastructure. The Rockville acquisition was seen as a step to narrow that gap, but the report described its scale as limited relative to total capacity.

During the policy effective-date windows, set for July 31, 2026 for large companies and September 29, 2026 for smaller ones, supply-chain plan submissions were concentrated, and the report warned that new contract signings could slow.

The 2025 full-year order total was reported at KRW 6.82 trillion, and 2026 order wins have been viewed as lagging by comparison. Some in the market read the post-BIOSECURE environment as an early sign of volume moving to Asian allied-country suppliers.

Among global CDMO peers, Lonza and Thermo Fisher Scientific compete in the same arena. As of the Q3 2026 disclosure, cumulative orders stood at 117 CMO projects and 184 CDO projects.

06

Outlook

On its October 21, 2026 disclosure, the company raised its annual revenue growth guidance to 20% from the previous 15 to 20% range.

The drivers it cited were full operation at Plants 1 to 4, qualification-batch revenue recognition at Plant 5 in the second half, and stabilization of commercial production at the Rockville facility.

Rockville capacity was not included in the guidance at the time of an April 2026 brokerage review, so some read the upgrade as tied to Rockville revenue starting in Q3.

On the sixth plant, a September 2026 report quoted company comments that construction could begin within the year if non-binding contracts convert to binding ones in sequence, and that the planned facility investment from the recent rights offering supports this.

On orders, a contract worth about KRW 434.3 billion was disclosed on November 3, 2026, and an existing contract was increased by about KRW 30.3 billion in the same two-day span. On peptide CDMO, the company secured 87.88% of PolyPeptide Group shares in the tender offer and is approaching final acquisition.

In a September 2026 report, Daol Investment & Securities analyst Lee Ji-su said enterprise value depends on returns from the raised capital and on a recovery in new orders, while describing the medium- to long-term growth direction as intact.

The dates the company has pointed to are the Plant 5 qualification-batch revenue and the timing of the sixth plant, both expected around the end of 2026.

07

Valuation

PER
36.3×
PBR
7.5×
ROE
17.3%
EPS
₩38,905
BPS
₩187,710
Dividend per share
₩0

Valuation should be read against both annual results and the recent quarterly trend. Profit attributable to controlling shareholders rose from KRW 798.1 billion in 2022 to KRW 1.78 trillion in 2025, but it has declined for four consecutive quarters since Q3 2025.

Earnings-based multiples therefore look different depending on whether the annual base or the last four quarters is used. The price-to-book ratio sits in a range with a large premium over controlling-shareholder equity, and the stock offers little dividend-based income.

The operating margin reaching 45.4% in 2025 confirms a change in earnings capacity, while revenue growth of 0.2% that year points to slower top-line expansion. How the market reads the share price will depend on how quickly the gap between the raised revenue guidance and a recovery in new orders closes.

In May 2026, Samsung Securities, using a DCF-based valuation, said it expected a real recovery in order momentum after Q3 2026.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Earnings recovery and a higher guidance

Q3 2026 revenue reached KRW 1.49 trillion and operating profit KRW 640.1 billion, with both rising for three straight quarters. The company raised its annual revenue growth guidance to 20%, citing full operation at Plants 1 to 4, higher utilization at Plant 5 and Rockville revenue. The 2025 operating margin of 45.4%, versus 29.0% in 2024, also signals a change in earnings capacity.

Order recovery and visibility on the sixth plant

The contract disclosed on November 3, 2026, worth about KRW 434.3 billion, was reported as the largest order disclosed this year, lifting cumulative orders to USD 22.3 billion. Company comments said construction of the sixth plant could begin within the year if non-binding contracts convert to binding ones. An existing contract was also increased by about KRW 30.3 billion in the same period.

Financial capacity and cash generation

At year-end 2025, equity totaled KRW 7.45 trillion and liabilities KRW 3.61 trillion, with the debt ratio falling from 84.6% in 2022 to 48.4% in 2025. With a large acquisition and capacity expansion under way, this financial capacity can be viewed as a supporting factor.

09

Bear factors

Profit attributable to shareholders down four quarters in a row

Profit attributable to controlling shareholders fell from KRW 574.5 billion in Q3 2025 to KRW 391.1 billion in Q3 2026, declining for four consecutive quarters. Q3 2026 profit attributable to controlling shareholders was down 31.9% year on year.

Profit falling while revenue and operating profit rise is a bearish point that calls for a close look at the detailed earnings structure.

Order gap and global competition

The 2025 full-year order total was reported at KRW 6.82 trillion, while cumulative 2026 orders as of November 3 were reported at about KRW 1.5 trillion (USD 1.1 billion). Confirming an order recovery on an annual basis will require further contract disclosures through year-end. Global CDMO rivals Lonza and Thermo Fisher Scientific compete in the same market.

Policy uncertainty and the US production base

As tariff and drug pricing policies shift, pharmaceutical companies are reviewing a move to US production. Samsung Securities, in a May 2026 report, said a company with limited US capacity will find it hard to close the gap quickly with rivals that have large US infrastructure. Despite the Rockville acquisition, the report judged its scale limited relative to total capacity.

10

Risk factors

Policy and regulatory risk

US tariff and drug pricing agreements can change contract terms and volume allocation. A May 2026 report pointed to remaining uncertainty over how contract terms will be set until policy standards become clear. As volume shifts toward US production, the scale of US manufacturing sites becomes more important.

Capital allocation and acquisition risk

The PolyPeptide Group acquisition was reported at about KRW 2.7 trillion, and proceeds from the recent rights offering are planned for facilities and the deal. Until integration results and returns on the raised capital are visible, financial burden and potential share dilution remain. Daol Investment & Securities noted that enterprise value will depend on returns from the raised funds.

Ramp-up and contract concentration risk

If Plant 5 ramp-up slows or stabilization of commercial production at Rockville is delayed, revenue recognition in the second half could slip. Individual contracts run to several hundred billion won, so a change in one contract's terms or timing can affect quarterly results. Without further new-contract disclosures, the basis for the sixth plant expansion would also weaken.

11

What to watch next

  1. By end of December 2026

    Whether Plant 5 qualification-batch revenue and stabilization of commercial production at Rockville show up in Q4 revenue. These are key indicators for whether the second-half revenue path supports the 20% guidance.

  2. By end of December 2026

    Whether construction of the sixth plant starts and how quickly non-binding contracts convert to binding ones. A start within the year would raise visibility on capacity expansion.

  3. Around late January 2027 (typical timing)

    Whether the decline in profit attributable to controlling shareholders stops in the Q4 and full-year 2026 preliminary results. The key is whether the gap between operating profit and net profit narrows.

  4. End of March 2027

    The 2026 annual business report is due on DART, the next regular filing with confirmed full-year 2026 results. It is the next checkpoint on a filed-results basis.

12

Overall view

From 2022 to 2025, Samsung Biologics recorded rising revenue, operating profit and profit attributable to controlling shareholders, and the 2025 operating margin rose sharply to 45.4%.

In 2026, revenue and operating profit have also risen for three straight quarters, and the company raised its annual revenue growth guidance to 20%. Profit attributable to controlling shareholders, however, has fallen for four consecutive quarters and was down 31.9% year on year in Q3 2026.

Cumulative orders rose to USD 22.3 billion after the November 3, 2026 contract, but 2026 order wins remain low compared with the 2025 full-year total. Items to confirm next are Plant 5 revenue recognition, stabilization at Rockville, the timing of the sixth plant and completion of the PolyPeptide acquisition.

As US policy raises the importance of local production, the strength of the US manufacturing base could affect competitiveness. This report summarizes facts from disclosures and press coverage and does not include a buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. alphabiz.co.kr
  2. getnews.co.kr
  3. fortunekorea.co.kr
  4. businesskorea.co.kr
  5. m.news.nate.com
  6. medicaldaily.co.kr
  7. inthenews.co.kr
  8. ftoday.co.kr
  9. todaymild.com
  10. datanews.co.kr
  11. biotimes.co.kr
  12. asiatoday.co.kr
  13. samsungpop.com
  14. ddaily.co.kr
  15. etoday.co.kr
  16. biz.heraldcorp.com
  17. pharm.edaily.co.kr
  18. news.bizwatch.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis